Portola Pharmaceuticals

Portola Pharmaceuticals was a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for patients with acute and chronic cardiovascular, autoimmune, and inflammatory diseases. The company's lead programs centered on anticoagulation and thrombosis, with its most notable product being Andexxa (andexanet alfa), the first approved antidote for reversal of Factor Xa inhibitors including rivaroxaban and apixaban. Portola also developed Bevyxxa (betrixaban), a Factor Xa inhibitor approved for VTE prophylaxis. The company was founded by Charles J. Homcy and David Phillips and was headquartered in South San Francisco, California. Portola was acquired by Alexion Pharmaceuticals in 2020, and portola.com now redirects to the Alexion website.